I mentioned on Monday that Kingfisher (KGF) was hosting a capital markets day this week. So how did it go?

Energy technology and services group Tekmar (TGP) is pleased to announce a “significant” new contract for an offshore wind farm project and emphasises it “builds on the encouraging contract momentum we have established, highlighted by the record order book of £20.1m we announced with our first half results”. So what of a current share price soaring up towards 12p?

I share a few thoughts with you - truths one cannot say in public - about the game last night. Notwithstanding that, I enjoyed the match, and the Northern Ireland girls held their heads up. Then, I discuss Canadian Overseas Petroleum (COPL), explaining my Christmas sub-10p target - the shares really will halve from here. I look at Shield Therapeutics (STX), MGC Pharmaceuticals (MXC), and Science in Sport (SIS) which, at every level, looks a stinker - even after today's 22% fall, the shares are grotesquely overvalued. I explain why. Finally, I describe why Malcolm should have learned from IQE (IQE) before continuing to tip Zoo Digital (ZOO) - as he has again done, today.

If you think that the worst for shares is over, think again, says analyst Chase Taylor

MGC Pharmaceuticals (MXC) is drowning in red flags, as I exposed HERE. Moreover, it is almost out of cash, as I noted HERE. Hence, it has today announced the seventh ramptastic RNS since May 27. Seven in six weeks is pretty good going, but the recent share slump - 2.25p six months ago, to 1.1p on May 27, to just 0.975p today - is even more telling.

The aquis-listed pot play, Love Hemp (LIFE) - backed by boxer, Anthony Joshua - committed fraud in February of this year. Its adviser, Peterhouse, rightly quit, leaving the shares suspended. Today, Love has reshuffled the corporate deckchairs and is talking to a new advisor, so people can trade its shares again. Which advisor is so bent that it will act for a demonstrable fraud?

The first cut is the least painful. That is to say, selling when it is clear a company is fecked, is less painful than waiting to sell in such circumstances. The document today published by Shield (STX) shows just how fecked it is.

Hello Share Gobblers. There were a few raised eyebrows this week when Zoo Digital (ZOO) said its full-year results would be delayed. You never know, when no further info is given, whether this sort of thing is a red flag or not. I opined that this was not likely here. I added that the share price, which stumbled on the news, offered a buying opportunity. Well, the results have now been posted only a day late.

Essentra (ESNT) has announced what it emphasises is “a significant step” to a future as a global leading manufacturer and distributor of components with a clear strategy and significant opportunities to accelerate growth and expand market share. This is with an agreed sale of its Packaging business.

Biopharma technology company Physiomics (PYC) has announced its year ended 30th June performance “in-line with market expectations” and expected increased revenue this year. So what of a current share price response more than 5% higher to above 3p?

Medical monitoring technology group Deltex Medical (DEMG) has issued a half-year trading update including “revenues for the six months ended 30 June 2022 increased approximately 9%” and that it expects to drive higher revenues. So what of a share price currently down more than 4% to 1.10p in response?

Ahead of my trip to Southampton, I discuss today's hilarious FinnCrap note on its client, Argo Blockchain (ARB) and Novacyt (NCYT), which is now worth less than net cash. I explain why. Then, it is onto Zoo Digital (ZOO): was the old codger, Malcolm Stacey, right to be so bullish? Er... no.

Radiation and bio-detection technology group Kromek (KMK) is “delighted to partner with Smiths Detection… to deliver our solutions to customers across North and South America”. So what of a share price response currently approaching 8% higher towards 10p?

June's operational update is truly shocking, and another red flag for the Argo Blockchain (ARB) collection. Natch, with Peter Wall in charge, the statement is disingenuous.

Back in January I wrote that “if you see Currys (CURY) shares at or below 100p…then buy them!”. A month or so later I did buy a few at about a 90p level. Naturally that has not worked despite the company being a thousand times better than AO World (AO.), something I am sure all you long/short investors would have observed. Still - on the former - it was good to see today’s full year numbers observing “a stronger Currys, doing more to help customers”, along with profit, free cash flow and negligible debt (in complete contrast to AO World naturally). However, naturally also, prospects for the year to April 2023 are somewhat lower than the year being reported on.

Sales are vanity, profits come down to opinion. Cash, however, is a matter of fact. In that vein, one wonders if, after today’s dismal trading statement, Bidstack's (BIDS) moronic shareholders can do basic maths. If they can, they will sell their shares first thing.

The notion that Sam Smith quit in order to get her leg over, is this morning blown out of the water by a Peel Hunt AGM warning. If Peel is getting battered, how do you think its notably inferior rival, FinnCap, is doing? When is your warning, your smugness? With results in the next couple of weeks, I suggest.

Hello Share Shifters. Given the wobbliness of the markets, it probably pays to seek out defensive shares i.e. those that can withstand the rigours of a recession. One such candidate for your attention is Dechra (DPH). This is a pharmaceuticals company that serves animals. And we all know that, in Blighty, one of the last thing people will curtail their spending on is the health of their pets.

Writing a year ago on UK bowling and ‘family entertainment’ centres group Ten Entertainment (TEG) I concluded with the shares at 248p whilst the demand situation normalises, currently on the watchlist. So what about now, following a trading update for its half year ended 26th June 2022?

Results for the year to April 3 2022 - out today from Procook (PROC) - were made irrelevant when, on 10 June this year, the company issued a dire profits warning.  But for what it's worth, the results are shite.